Sarah Sportiche1,2,3, Pierre Alexis Geoffroy1,2,3,4,5, Clara Brichant-Petitjean1,2,3, Sebastien Gard3,6, Jean-Pierre Khan3,7,8, Jean-Michel Azorin3,9,10, Chantal Henry3,11,12, Marion Leboyer3,11, Bruno Etain1,2,3,4, Jan Scott13,14, Frank Bellivier1,2,3,4. 1. 1 Inserm, U1144, Paris, France. 2. 2 AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, Paris, France. 3. 3 Fondation FondaMental, Créteil, France. 4. 4 Université Paris Diderot and Sorbonne Paris Cité, UMR-S 1144, Paris, France. 5. 5 Université Paris Descartes, UMR-S 1144, Paris, France. 6. 6 Hôpital Charles Perrens, Centre Expert Bipolaire, Pôle de Psychiatrie Générale Universitaire, Bordeaux, France. 7. 7 Service de Psychiatrie et Psychologie Clinique, CHU de Nancy, Centre Psychothérapique de Nancy-Laxou, Nancy, France. 8. 8 Université de Lorraine, Nancy, France. 9. 9 Pôle de psychiatrie, Hôpital Sainte Marguerite, Assistance Publique Hôpitaux de Marseille, Marseille, France. 10. 10 EA 3279-Self-perceived Health Assessment Research Unit, School of Medicine, Timone University, Marseille, France. 11. 11 Inserm, U955, Equipe de psychiatrie génétique et Université Paris Est, Faculté de médecine et AP-HP, Pôle de psychiatrie, Hôpitaux Universitaires Henri Mondor, Créteil, France. 12. 12 Institut Pasteur, Unité Perception et Mémoire, Paris, France. 13. 13 Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK. 14. 14 Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), London, UK.
Abstract
BACKGROUND: Bipolar disorder is a common chronic illness characterized by high levels of morbidity and all-cause mortality. Lithium is one of the gold standard mood stabilizer treatments, but the identification of good, partial and non-responders in clinical settings is inconsistent. METHODS: We used an established rating scale (the Alda scale) to classify the degree of lithium response (good response, partial response, non-response) in a large, multicentre clinically representative sample of well-characterized cases of bipolar disorders I and II. Next, we examined previously reported clinical predictors of response to determine which factors significantly differentiated between the three response groups. RESULTS: Of 754 cases, 300 received lithium, for at least 6 months, as a treatment for bipolar disorder (40%). Of these cases, 17% were classified as good response, 52% as partial response and 31% as non-response. Lifetime history of mixed episodes ( p = 0.017) and alcohol use disorders ( p = 0.015) both occurred in >20% of partial response and non-response groups but <10% of good response cases. Family history of bipolar disorder I was of borderline statistical significance, being more frequent in the good response group (38%) compared with the non-response group (18%). There was a trend ( p = 0.06) for bipolar disorder II to be associated with non-response. CONCLUSIONS: Only three factors previously identified as predictors of lithium response significantly differentiated the response groups identified in our sample. Interestingly, these factors have all been found to co-occur more often than expected by chance, and it can be hypothesized that they may represent a shared underlying factor or dimension. Further prospective studies of predictors and the performance of the Alda scale are recommended.
BACKGROUND:Bipolar disorder is a common chronic illness characterized by high levels of morbidity and all-cause mortality. Lithium is one of the gold standard mood stabilizer treatments, but the identification of good, partial and non-responders in clinical settings is inconsistent. METHODS: We used an established rating scale (the Alda scale) to classify the degree of lithium response (good response, partial response, non-response) in a large, multicentre clinically representative sample of well-characterized cases of bipolar disorders I and II. Next, we examined previously reported clinical predictors of response to determine which factors significantly differentiated between the three response groups. RESULTS: Of 754 cases, 300 received lithium, for at least 6 months, as a treatment for bipolar disorder (40%). Of these cases, 17% were classified as good response, 52% as partial response and 31% as non-response. Lifetime history of mixed episodes ( p = 0.017) and alcohol use disorders ( p = 0.015) both occurred in >20% of partial response and non-response groups but <10% of good response cases. Family history of bipolar disorder I was of borderline statistical significance, being more frequent in the good response group (38%) compared with the non-response group (18%). There was a trend ( p = 0.06) for bipolar disorder II to be associated with non-response. CONCLUSIONS: Only three factors previously identified as predictors of lithium response significantly differentiated the response groups identified in our sample. Interestingly, these factors have all been found to co-occur more often than expected by chance, and it can be hypothesized that they may represent a shared underlying factor or dimension. Further prospective studies of predictors and the performance of the Alda scale are recommended.
Authors: Ahsan Habib; R Douglas Shytle; Darrell Sawmiller; Selina Koilraj; Sadia Afrin Munna; David Rongo; Huayan Hou; Cesario V Borlongan; Glenn Currier; Jun Tan Journal: J Neurosci Res Date: 2019-05-17 Impact factor: 4.164
Authors: Gabriel R Fries; Gabriela D Colpo; Nancy Monroy-Jaramillo; Junfei Zhao; Zhongming Zhao; Jodi G Arnold; Charles L Bowden; Consuelo Walss-Bass Journal: Eur Neuropsychopharmacol Date: 2017-09-20 Impact factor: 4.600
Authors: Andrew A Nierenberg; Meredith G Harris; Alan E Kazdin; Victor Puac-Polanco; Nancy Sampson; Daniel V Vigo; Wai Tat Chiu; Hannah N Ziobrowski; Jordi Alonso; Yasmin Altwaijri; Guilherme Borges; Brendan Bunting; José Miguel Caldas-de-Almeida; Josep Maria Haro; Chi-Yi Hu; Andrzej Kiejna; Sing Lee; John J McGrath; Fernando Navarro-Mateu; José Posada-Villa; Kate M Scott; Juan C Stagnaro; Maria C Viana; Ronald C Kessler Journal: Bipolar Disord Date: 2021-03-28 Impact factor: 5.345
Authors: Jan Scott; Diego Hidalgo-Mazzei; Rebecca Strawbridge; Allan Young; Matthieu Resche-Rigon; Bruno Etain; Ole A Andreassen; Michael Bauer; Djamila Bennabi; Andrew M Blamire; Fawzi Boumezbeur; Paolo Brambilla; Nadia Cattane; Annamaria Cattaneo; Marie Chupin; Klara Coello; Yann Cointepas; Francesc Colom; David A Cousins; Caroline Dubertret; Edouard Duchesnay; Adele Ferro; Aitana Garcia-Estela; Jose Goikolea; Antoine Grigis; Emmanuel Haffen; Margrethe C Høegh; Petter Jakobsen; Janos L Kalman; Lars V Kessing; Farah Klohn-Saghatolislam; Trine V Lagerberg; Mikael Landén; Ute Lewitzka; Ashley Lutticke; Nicolas Mazer; Monica Mazzelli; Cristina Mora; Thorsten Muller; Estanislao Mur-Mila; Ketil Joachim Oedegaard; Leif Oltedal; Erik Pålsson; Dimitri Papadopoulos Orfanos; Sergi Papiol; Victor Perez-Sola; Andreas Reif; Philipp Ritter; Roberto Rossi; Thomas Schulze; Fanny Senner; Fiona E Smith; Letizia Squarcina; Nils Eiel Steen; Pete E Thelwall; Cristina Varo; Eduard Vieta; Maj Vinberg; Michele Wessa; Lars T Westlye; Frank Bellivier Journal: Int J Bipolar Disord Date: 2019-09-25
Authors: Azmeraw T Amare; Klaus Oliver Schubert; Liping Hou; Scott R Clark; Sergi Papiol; Micah Cearns; Urs Heilbronner; Franziska Degenhardt; Fasil Tekola-Ayele; Yi-Hsiang Hsu; Tatyana Shekhtman; Mazda Adli; Nirmala Akula; Kazufumi Akiyama; Raffaella Ardau; Bárbara Arias; Jean-Michel Aubry; Lena Backlund; Abesh Kumar Bhattacharjee; Frank Bellivier; Antonio Benabarre; Susanne Bengesser; Joanna M Biernacka; Armin Birner; Clara Brichant-Petitjean; Pablo Cervantes; Hsi-Chung Chen; Caterina Chillotti; Sven Cichon; Cristiana Cruceanu; Piotr M Czerski; Nina Dalkner; Alexandre Dayer; Maria Del Zompo; J Raymond DePaulo; Bruno Étain; Stephane Jamain; Peter Falkai; Andreas J Forstner; Louise Frisen; Mark A Frye; Janice M Fullerton; Sébastien Gard; Julie S Garnham; Fernando S Goes; Maria Grigoroiu-Serbanescu; Paul Grof; Ryota Hashimoto; Joanna Hauser; Stefan Herms; Per Hoffmann; Andrea Hofmann; Esther Jiménez; Jean-Pierre Kahn; Layla Kassem; Po-Hsiu Kuo; Tadafumi Kato; John R Kelsoe; Sarah Kittel-Schneider; Sebastian Kliwicki; Barbara König; Ichiro Kusumi; Gonzalo Laje; Mikael Landén; Catharina Lavebratt; Marion Leboyer; Susan G Leckband; Alfonso Tortorella; Mirko Manchia; Lina Martinsson; Michael J McCarthy; Susan L McElroy; Francesc Colom; Marina Mitjans; Francis M Mondimore; Palmiero Monteleone; Caroline M Nievergelt; Markus M Nöthen; Tomas Novák; Claire O'Donovan; Norio Ozaki; Urban Ösby; Andrea Pfennig; James B Potash; Andreas Reif; Eva Reininghaus; Guy A Rouleau; Janusz K Rybakowski; Martin Schalling; Peter R Schofield; Barbara W Schweizer; Giovanni Severino; Paul D Shilling; Katzutaka Shimoda; Christian Simhandl; Claire M Slaney; Alessio Squassina; Thomas Stamm; Pavla Stopkova; Mario Maj; Gustavo Turecki; Eduard Vieta; Julia Veeh; Stephanie H Witt; Adam Wright; Peter P Zandi; Philip B Mitchell; Michael Bauer; Martin Alda; Marcella Rietschel; Francis J McMahon; Thomas G Schulze; Bernhard T Baune Journal: Mol Psychiatry Date: 2020-03-16 Impact factor: 13.437